详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A novel fourth generation of CAR-T cells: CD19 CAR-T cells engineered to express membrane-bound interleukin-15 and CXCR5 for the treatment of lymphoma

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin 300070, China [2]School of Medicine, Nankai University, Tianjin 300071, China [3]Tianjin Thrombosis and Hemostasis Institute，Department of Hematology, Tianjin First Central Hospital, No. 2, Baoshanxi Road, Xiqing District, Tianjin 300392, China [4]Department of Cardiovascular Medicine, Pujiang People’s Hospital, Chengdu 611630, Sichuan, China

出处：

DOI：

ISSN：

关键词： B-cell lymphoma Membrane-bound interleukin-15 CXCR5 CAR-T Immunotherapy

摘要：

The efficacy of CD19 CAR-T cells in B-cell lymphoma patients is not as good as that in B-cell acute lymphoblastic leukemia (B-ALL) patients. This might be attributed to the intricate tumor microenvironment of B-cell lymphoma, which leads to CAR-T cell exhaustion, inability to sustain function, and difficulty infiltrating into the tumor interior. We developed CD19 CAR structures that simultaneously produce membrane-bound IL-15 (mbIL-15) and CXCR5. This design aims to enhance the migration of CAR-T cells into CXCL13+ B-cell lymphomas and their long-term antitumor ability. Compared with CD19 CAR-T cells, CD19 mbIL15-CXCR5 CAR-T cells exhibited greater cytotoxicity against CD19+ tumor cell lines in vitro. In particular, when exposed to recurrent tumor antigen stimulation, CD19 mbIL15-CXCR5 CAR-T cells still exerted long-lasting antitumor effects. CD19 mbIL15-CXCR5 CAR-T cells had a greater proportion of central memory T (TCM) and effector memory T (TEM) cells, which allowed them to exhibit more long-lasting antitumor effects. Moreover, in Transwell assays and mouse models, compared with CD19 CAR-T cells, CD19 mbIL15-CXCR5-CAR-T cells exhibited significant chemotaxis toward CXCL13+ tumor cells and superior tumor infiltration ability. The Xenogram animal model demonstrated better and more persistent tumor suppression ability than did the CD19 CAR-T cells. We preliminarily demonstrated the safety of CD19 mbIL15-CXCR5-CAR-T cells in vivo by evaluating liver and kidney function and major organ morphology in mice. In summary, the use of CD19 mbIL15-CXCR5-CAR-T cells is a relatively safe and effective option for the treatment of B-cell malignancies.© 2025. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

最新[2025]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

第一作者：

第一作者机构： [1]First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin 300070, China [4]Department of Cardiovascular Medicine, Pujiang People’s Hospital, Chengdu 611630, Sichuan, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. [2]Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. [3]桥接治疗在大b细胞淋巴瘤car-t治疗中的应用进展 [4]Multimodal profiling identifies CD4+CXCR5+PD-1- Tfh cells as prognostic and predictive biomarkers in diffuse large B-cell lymphoma [5]New Approaches in CAR-T Cell Immunotherapy for Breast Cancer [6]Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy [7]Time to abandon CAR-T monotherapy for solid tumors [8]Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies. [9]Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives [10]Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)